Trial of Deferiprone in Parkinson's Disease.
David DevosJulien LabreucheOlivier RascolJean-Christophe CorvolAlain DuhamelPauline Guyon DelannoyWerner PoeweYaroslau ComptaNicola PaveseEvžen RůžičkaPetr DušekBart PostBastiaan R BloemDaniela BergWalter MaetzlerMarkus OttoMarie-Odile HabertStéphane LehericyJoaquim FerreiraRichard DodelChristine TranchantAlexandre EusebioStéphane ThoboisAna-Raquel MarquesWassilios G MeissnerFabienne Ory-MagneUwe WalterRob M A de BieMiguel GagoDolores VilasJaime KulisevskyCristina JanuarioMiguel V S CoelhoStefanie BehnkePaul WorthKlaus SeppiThavarak OukCamille PoteyCéline LeclercqRomain ViardGregory KuchcinskiRenaud LopesJean-Pierre PruvoPascal PignyGuillaume GarçonOphélie SimoninJessica CarpentierAnne-Sophie RollandDag NyholmChristoph ScherflerJean-François ManginMarie ChupinRégis BordetDavid T DexterCaroline FradetteMichael SpinoFernando TrictaScott Jonathan AytonAshley I BushJean-Christophe DevedjianJames A DuceIoav CabantchikLuc DefebvreDominique DeplanqueCaroline Moreaunull nullPublished in: The New England journal of medicine (2022)
In participants with early Parkinson's disease who had never received levodopa and in whom treatment with dopaminergic medications was not planned, deferiprone was associated with worse scores in measures of parkinsonism than those with placebo over a period of 36 weeks. (Funded by the European Union Horizon 2020 program; FAIRPARK-II ClinicalTrials.gov number, NCT02655315.).